Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting the chromatin remodeler BAZ2B mitigates liver aging and fibrosis

ABSTRACT: Targeting the chromatin remodeler BAZ2B mitigates liver aging and fibrosis

PROVIDER: PRJNA1179915 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR31165043_1.fastq.gz	Fastqsanger.gz
	SRR31165043_2.fastq.gz	Fastqsanger.gz
	SRR31165044_1.fastq.gz	Fastqsanger.gz
	SRR31165044_2.fastq.gz	Fastqsanger.gz
	SRR31165045_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 92

Similar Datasets

Targeting the chromatin remodeler BAZ2B mitigates liver aging and fibrosis

Project description:Increasing age enhances the liver's vulnerability to nonalcoholic steatohepatitis (NASH) with fibrosis. Unraveling the intricate molecular relationship among aging, cellular senescence, and NASH is critical for developing effective treatments, yet it remains a daunting challenge. Here we report a vital epigenetic mechanism that links liver aging to NASH fibrosis. We find that up-regulation of a chromatin remodeler BAZ2B in a subpopulation of hepatocytes contributes to the pathological progression of NASH in patients. Genetic ablation or hepatocyte-specific knockdown of Baz2b rejuvenates hepatic cells and limits diet-induced steatohepatitis and liver fibrosis via preserving the peroxisome proliferator-activated receptor α (PPARα)-mediated lipid metabolism, which was impaired in both naturally aging and NASH mouse livers. Mechanistically, Baz2b down-regulates the expression of genes related to the PPARα signaling pathway by directly binding their promoter regions and reducing chromatin accessibility. Our study thus unravels the BAZ2B-PPARα-lipid-metabolism signal axis as a key pathway linking liver aging to NASH fibrosis, suggesting that BAZ2B is a potential therapeutic target for hepatic fibrosis.

2025-03-12 | GSE280663 | GEO

Exercise Mitigates Skeletal Muscle Epigenetic Aging

Project description:Exercise late in life mitigates skeletal muscle epigenetic aging, providing evidence that physical activity is a "fountain of youth".

2021-12-31 | GSE175410 | GEO

Exercise Mitigates Skeletal Muscle Epigenetic Aging

Project description:Exercise Mitigates Skeletal Muscle Epigenetic Aging

| PRJNA732356 | ENA

Expression data from Hap1 parental control and Baz2B-KO cell lines

Project description:Baz2B protein was shown to form a chromatin remodelig complex mit Snf2H or Snf2L catalytic subunits. It is known that chromatin remodeling proteins regulate diffferent DNA-templated processes, therefore we wanted to know whether Baz2B plays a role in transcription regulation. We used microarrays to detail the global expression of transcripts in Hap1 parental cell line and compare them to Baz2B-KO. We found up- and down-regulated trasncripts that could be associated with the decreased cellular proliferation in Baz2B-KO cell line

2023-11-27 | GSE218705 | GEO

Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart

Project description:Inhibition of Eicosanoid Degradation Mitigates Fibrosis of the Heart

| PRJNA901468 | ENA

Bazi Bushen extents health span and mitigates epigenetic aging in nature aging mice

Project description:Bazi Bushen extents health span and mitigates epigenetic aging in nature aging mice

| PRJNA889745 | ENA

ATAC-seq analyses to study chromatin state after overexpression of BAZ2B in lineage-committed human hematopoietic progenitors

Project description:We demonstrated that the overexpression of BAZ2B in human lineage-committed progenitors lead to an induction of reprogramming to a multipotent hematopoietic stem cell state. To understand the mechanism we overexpressed Luciferase or BAZ2B in lineage-committed progenitors for 14 days and performed the ATAC-seq experiments

2020-11-12 | GSE151634 | GEO

The effects of Baz2b-knockout on doxorubicin-induced cardiotoxicity

Project description:The study used wild type (WT) and Baz2b-knockout (KO) mice to establish a subacute doxorubicin (DOX)-induced cardiotoxicity model by intraperitoneal injection for 6 times in 2 weeks. Mice injected with equivalent PBS were used as the control group.

2025-06-24 | GSE236165 | GEO

Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa

Project description:Recessive dystrophic epidermolysis bullosa (RDEB) is a mucocutaneous blistering disease due to type VII collagen gene mutations. Transforming growth factor-β (TGF-β)-dependent fibrosis is responsible for severe RDEB complications. Reduced histone acetylation is a hallmark of fibrosis in pathologies affecting organs other than skin, where inhibition of histone deacetylses (HDACs) proved effective in reverting fibrosis. Here, HDAC inhibitor (HDACi) ability to counteract RDEB progression was investigated. We found that histone acetylation is decreased in RDEB skin and fibroblasts. Treatment with two HDACis, valproic acid (VPA) and Givinostat, counteracts RDEB fibroblast fibrotic traits, including contractility, α-smooth muscle actin expression, TGF-β1 release, and proliferation. Moreover, systemic VPA administration mitigates severe manifestations (corneal opacification and digit loss) in a RDEB mouse model. This effect associates with inhibition of skin fibrosis (presence of subcutaneous fat, thinner collagen bundles, decreased expression of fibrotic markers). Proteomic analysis of mouse skin revealed that VPA treatment decreases expression of genes involved in protein synthesis and increases levels of proteins with role in immune response. These findings highlight epigenetic changes as contributing to RDEB pathogenesis and disclose molecular mechanisms leading to skin fibrosis. Treatment with HDACi may represent a disease modifier therapeutic approach for RDEB and other skin fibrotic disorders.

2024-09-02 | GSE239569 | GEO

Role of diet in cardiac aging and fibrosis

Project description:Role of diet in cardiac aging and fibrosis

| PRJNA559176 | ENA